Brightli

Brightli, Burrell Behavioral Health

In the 2025 National Directory of Mental Health Treatment Facilities.

Type of Care

Mental health treatment (MH); Treatment for co-occurring substance use plus either serious mental illness (SMI) in adults and/or serious emotional disturbance (SED) in children (SUMH)

Service Setting

Residential/24-hour residential (RES)

Facility Type

Residential treatment center (RTC) for adults (RTCA)

Pharmacotherapies

Fluphenazine (FLUPH); Haloperidol (HALOP); Loxapine (LOXAP); Aripiprazole (ARIPI); Clozapine (CLOZA); Lurasidone (LURAS); Olanzapine (OLANZ); Paliperidone (PALIP); Quetiapine (QUETI); Risperidone (RISPE); Ziprasidone (ZIPRA); Antipsychotics used in treatment of SMI (ANTPYCH)

Treatment Approaches

Group therapy (GT); Individual psychotherapy (IPT)

Facility Operation (e.g., Private, Public)

Private non-profit organization (PVTN)

Payment/Insurance/Funding Accepted

Medicare (MC); Medicaid (MD)

Special Programs/Groups Offered

Persons 18 and older with serious mental illness (SMI) (SMI)

Recovery Support Services

Housing services (HS)

Facility Smoking Policy

Smoking permitted in designated area (SMPD)

Age Groups Accepted

Young Adults (YAD); Seniors (SNR)

Facility Vaping Policy

Vaping permitted in designated area (VPPD)

Ancillary Services

Court-ordered outpatient treatment (COOT); Supported housing (SH); Case management service (CM); Education services (ES)